Chronic cough, defined as a cough that persists for over eight weeks, is a common yet perplexing clinical scenario. Not only does it cause significant patient discomfort, but its etiology can be multifactorial and difficult to ascertain. This article aims to provide a comprehensive approach to the evaluation and management of chronic cough.
Chronic cough can be a symptom of an underlying systemic disease or a primary disorder of the cough reflex. The most common causes include asthma, gastroesophageal reflux disease (GERD), and upper airway cough syndrome (UACS). However, the mechanism may also be idiopathic, or the result of a hypersensitive cough reflex.
A thorough history and physical examination are crucial in the initial evaluation. This should be followed by a structured diagnostic approach, beginning with common causes and progressing to more rare conditions if necessary. Empiric treatment trials for asthma, GERD, and UACS can be considered. If the cough persists, further testing such as chest imaging, spirometry, or bronchoscopy may be warranted.
Treatment of chronic cough should aim to address the underlying cause. This may involve pharmacologic therapies such as bronchodilators for asthma, proton pump inhibitors for GERD, or antihistamines for UACS. In refractory cases, non-pharmacologic therapies such as speech therapy or behavioral interventions can be beneficial. Furthermore, recent advances in understanding the neurophysiology of cough have led to the development of novel cough suppressants targeting specific neural pathways.
Chronic cough is a complex clinical problem that requires a comprehensive approach to diagnosis and treatment. By understanding the underlying mechanisms and adopting a structured diagnostic approach, healthcare professionals can more effectively manage this challenging condition. Continued research into the neurophysiology of cough will likely yield further advances in treatment strategies.
1.
What is a "cancer vaccine" and is it the same as a COVID vaccine?
2.
Advances in "next generation" photoactive cancer therapy
3.
Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.
4.
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis
5.
FDA Approves New Bladder Cancer First-Line Standard of Care.
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
The latest research on Iron Binding Capacity: The Little-Known Factor That Could Impact Your Health v
3.
The latest Hematocrit: An Overview of Red Blood Cell Health
4.
Contemporary Trends in Oncology and Patient Outcomes
5.
Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
2.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
3.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation